|
Name |
penicillidione B
|
| Molecular Formula | C17H19NO4 | |
| IUPAC Name* |
5-ethyl-2-hydroxy-6-[(2-hydroxyanilino)methylidene]-2,4-dimethylcyclohex-4-ene-1,3-dione
|
|
| SMILES |
CCC1=C(C)C(=O)C(C)(O)C(=O)C1=CNc1ccccc1O
|
|
| InChI |
InChI=1S/C17H19NO4/c1-4-11-10(2)15(20)17(3,22)16(21)12(11)9-18-13-7-5-6-8-14(13)19/h5-9,18-19,22H,4H2,1-3H3/b12-9-/t17-/m1/s1
|
|
| InChIKey |
SPFYZAIZXBJIJS-QJWNTBNXSA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Molecular Weight: | 301.34 | ALogp: | 2.3 |
| HBD: | 3 | HBA: | 5 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 86.6 | Aromatic Rings: | 2 |
| Heavy Atoms: | 22 | QED Weighted: | 0.454 |
| Caco-2 Permeability: | -4.724 | MDCK Permeability: | 0.00001630 |
| Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.945 |
| Human Intestinal Absorption (HIA): | 0.026 | 20% Bioavailability (F20%): | 0.985 |
| 30% Bioavailability (F30%): | 0.685 |
| Blood-Brain-Barrier Penetration (BBB): | 0.718 | Plasma Protein Binding (PPB): | 80.93% |
| Volume Distribution (VD): | 0.973 | Fu: | 11.24% |
| CYP1A2-inhibitor: | 0.13 | CYP1A2-substrate: | 0.356 |
| CYP2C19-inhibitor: | 0.045 | CYP2C19-substrate: | 0.781 |
| CYP2C9-inhibitor: | 0.072 | CYP2C9-substrate: | 0.654 |
| CYP2D6-inhibitor: | 0.062 | CYP2D6-substrate: | 0.088 |
| CYP3A4-inhibitor: | 0.876 | CYP3A4-substrate: | 0.867 |
| Clearance (CL): | 4.922 | Half-life (T1/2): | 0.533 |
| hERG Blockers: | 0 | Human Hepatotoxicity (H-HT): | 0.074 |
| Drug-inuced Liver Injury (DILI): | 0.965 | AMES Toxicity: | 0.283 |
| Rat Oral Acute Toxicity: | 0.922 | Maximum Recommended Daily Dose: | 0.012 |
| Skin Sensitization: | 0.183 | Carcinogencity: | 0.733 |
| Eye Corrosion: | 0.879 | Eye Irritation: | 0.51 |
| Respiratory Toxicity: | 0.974 |